Aprogen Completes 10 Billion Won Convertible Bond Issuance…Dilution Risk Persists
Aprogen announced the completion of its 31st unregistered private convertible bond issuance worth 10 billion won (payment completed on May 29, 2026).
The CB was initially resolved on May 21, 2026, with a conversion price of 5,350 won (31.6% premium to the then market price of 4,065 won).
The conversion price can be adjusted downward to a minimum of 3,745 won (70% of initial) if the stock price falls, implying potential dilution risk at the current price of 3,960 won.
Combined with existing outstanding CBs of 142 billion won, total potential diluted shares reach 34.97 million, representing 148% of current outstanding shares (22.42 million), signaling severe dilution overhang.
Proceeds from this issuance will be used to acquire equity in a third party (Aprogen Biologics).
[AI Comprehensive Analysis]The completion of this CB issuance was already expected and does not bring new shock to the market. However, the combined potential dilution of 148% from all outstanding CBs remains a significant risk factor limiting upside potential. Investors should monitor whether further capital raising plans emerge and the timing of conversion rights exercise, as it could intensify downward price pressure.
KOSPI Filing Information
Filing: Result of Issuance of Rights Offering or Equity-Related Bonds (Voluntary Disclosure)